Compare ASRV & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASRV | PDSB |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.2M | 62.0M |
| IPO Year | 1994 | 2015 |
| Metric | ASRV | PDSB |
|---|---|---|
| Price | $4.41 | $0.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 13.5K | ★ 284.1K |
| Earning Date | 04-21-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ 61.90 | 28.16 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $14,634,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $38.09 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.64 | $0.51 |
| 52 Week High | $4.49 | $1.55 |
| Indicator | ASRV | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 69.72 | 33.58 |
| Support Level | $3.62 | $0.62 |
| Resistance Level | N/A | $0.73 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 78.08 | 21.32 |
AmeriServ Financial Inc is a bank holding company. The company and its subsidiaries derive substantially all of their income from banking, bank-related services, and trust-related services. Its operating segment includes community banking and it generates maximum revenue. The community banking segment includes both retail and commercial banking activities. The company also offers retail banking which includes the deposit-gathering branch franchise and lending to both individuals and small businesses; Lending activities include residential mortgage loans, direct consumer loans, and small business commercial loans; Commercial banking to businesses includes commercial loans, business services, and CRE loans.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.